Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Related Articles
Supporting Predictive Analytics to Improve Clinical Decision Making and Patient Outcomes
As we strive to improve clinical decison making and patient outcomes – predictive analytics are a wonderful tool to help us in that goal. But you can’t just decide to throw predictive analytics into…{post_date: F d, Y}
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…{post_date: F d, Y}
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…{post_date: F d, Y}
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.{post_date: F d, Y}